A groundbreaking study tracked 1613 patients with low-risk papillary thyroid carcinoma (PTC) who underwent radiofrequency ablation (RFA) for an impressive 58.5 months. Results unveiled a remarkable 4.3% local tumor progression rate, with a 95.7% disease-free survival at 8 years. Subcapsular tumor location and multifocality were risk factors, emphasizing RFA’s efficacy. Unifocal, smaller tumors correlated with complete disappearance. RFA demonstrated excellent long-term outcomes, offering potential as a prime treatment for select T1N0M0 PTC cases.
Journal Article by Li X, Yan L (…) Luo Y et 4 al. in JAMA Surg